FDA Renews Canalevia-CA1 for Chemotherapy Induced Diarrhea in Dogs Through 2026

Chemotherapy can be life saving for canine cancer patients, but anyone who has managed a dog with chemotherapy induced diarrhea knows how quickly GI side effects can derail treatment plans, stress pet parents, and drain clinic morale. That is why Jaguar Health’s latest news is worth your attention. The FDA has officially renewed the conditional approval of Canalevia-CA1, extending access to this targeted therapy for chemotherapy induced diarrhea in dogs through December 21, 2026.